• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 430642 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1413844787 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1413844787 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of Acadia Pharmaceuticals Rise Above Previous 52-Week High

Published on Mon, 01/28/2013 - 15:11
By Peter Chu

Acadia Pharmaceuticals (NASDAQ:ACAD) traded at a new 52-week high today of $6.67. Approximately 6.4 million shares have changed hands today, as compared to an average 30-day volume of 2.1 million shares.

In the past 52 weeks, shares of Acadia Pharmaceuticals have traded between a low of $1.29 and a high of $6.67 and are now at $6.62, which is 413% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 7.0% while the 200-day MA has risen 3.4%.

Potential upside of 26.2% exists for Acadia Pharmaceuticals, based on a current level of $6.62 and analysts' average consensus price target of $8.36. The stock should discover initial support at its 50-day moving average (MA) of $4.48 and subsequent support at its 200-day MA of $2.48.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Tenaris: The Losing Streak Continues (TS...

Tenaris (NYSE:TS) traded at a new 52-week low today of $37.56. This new low was reache ...

Shares of TECO Energy Rise Above Previou...

TECO Energy (NYSE:TE) traded today at a new 52-week high of $18.78. This new high was ...

Shares of Teck Resources Fall to a New 5...

Teck Resources (NYSE:TCK) traded today at a new 52-week low of $15.15. This new low wa ...

Strayer Education Looks to Continue to T...

Strayer Education (NASDAQ:STRA) traded at a new 52-week high today of $67.03. Approxim ...

Shares of Sonic Rise to a New 52-Week Hi...

Sonic (NASDAQ:SONC) traded at a new 52-week high today of $24.00. This new high was re ...

Shares of Cia Siderurgica Nacional Fall ...

Cia Siderurgica Nacional (NYSE:SID) traded today at a new 52-week low of $3.32. Approx ...

Shares of Steven Madden Fall Below Previ...

Shares of Steven Madden (NASDAQ:SHOO) traded today at $28.02, breaking its 52-week low. ...

Shares of SAP Fall to a New 52-Week Low...

SAP (NYSE:SAP) traded today at a new 52-week low of $64.10. Approximately 2.3 million ...